Search

Displaying results 5261 - 5270 of 7452 in total
  1. Drug

    Exebacase

    go.drugbank.com/drugs/DB16161
    Investigational

    Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia).

  2. Drug

    Fenpyroximate

    go.drugbank.com/drugs/DB16164
    Investigational

    Fenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania

  3. Drug

    Balsalazide

    go.drugbank.com/drugs/DB01014
    Approved

    Mesalazine is also known as 5-aminosalicylic acid, or 5-ASA.

  4. Drug

    Bisoctrizole

    go.drugbank.com/drugs/DB11262
    Approved

    Bisoctrizole, or methylene bis-benzotriazolyl tetramethylbutylphenol, is a broad-spectrum organic UV filter that is marketed as Tinosorb M [A19212].

  5. Drug

    RUS 3108

    go.drugbank.com/drugs/DB05911
    Experimental

    RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.

  6. Drug

    Dirlotapide

    go.drugbank.com/drugs/DB11399
    InvestigationalVet approved

    It is marketed by Pfizer and Zoetis under the brand name, _Slentrol_, and is not intended for human use.

  7. Drug

    tgAAVCF

    go.drugbank.com/drugs/DB17849
    Investigational

    It is being investigated for the treatment of cystic fibrosis.[A259821, A259826]

  8. Drug

    Tubercidin

    go.drugbank.com/drugs/DB03172
    Experimental

    An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids

  9. Drug

    Oxandrolone

    go.drugbank.com/drugs/DB00621
    ApprovedInvestigational

    A synthetic hormone with anabolic and androgenic properties.

    Categories: Anabolic Agents for Systemic Use
  10. Drug

    TRX1

    go.drugbank.com/drugs/DB05863
    Experimental

    TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.